Jaimes E A, Galceran J M, Raij L
Nephrology and Hypertension Section, Veterans Administration Medical Center and University of Minnesota, Minneapolis 55417, USA.
Kidney Int. 1998 Sep;54(3):775-84. doi: 10.1046/j.1523-1755.1998.00068.x.
The recognized role of angiotensin II (Ang II) in the pathogenesis of the progression of renal disease cannot be solely attributed to Ang II's hemodynamic effects. Indeed, growth stimulating signals driven by Ang II promote mesangial cell (MC) hypertrophy and extracellular matrix production, prominent features of progressive glomerular injury. Superoxide anion (O2-) avidly interacts with nitric oxide, an endogenous vasodilator that inhibits growth factor stimulated MC growth and matrix production. In addition, O2- acting as an intracellular signal is linked to growth related responses such as activation of mitogen activated protein (MAP) kinases. The studies reported herein were designed to investigate: (a) whether Ang II induces MC O2-production and (b) if increased O2- production elicits growth responses in MC.
MC were exposed to Ang II for 24 or 48 hours. In some experiments, in addition to Ang II, MC were exposed to: diphenylenieodonium (DPI), an inhibitor of the flavin containing NADH/NADPH oxidase; losartan (LOS), an Ang II type 1 (AT1) receptor blocker; PD 98059, a MAP kinases inhibitor; the protein kinase C inhibitors Calphostin C or H-7; and the tyrosine kinase inhibitors, herbymycin A or genistein.
Ang II (10(-5) M to 10(-8) M) dose dependently increased MC O2- production up to 125% above control (ED 50 5 x 10(-7) M). LOS as well as DPI, and the PKC inhibitors blocked Ang II stimulated MC O2- production. Ang II dose dependently increased MC 3H-leucine incorporation, and MC protein content, two markers of MC hypertrophy, as well as 3H-thymidine incorporation, a marker of MC hyperplasia. PD98059, a specific inhibitor of MAP kinases prevented Ang II induced MC hypertrophy. Moreover, LOS, DPI, and the PKC inhibitors each independently inhibited MC 3H-leucine incorporation, thereby establishing the specificity of Ang II induced O2- in driving MC hypertrophy.
The current studies demonstrate a previously unrecognized link between Ang II and MC O2- production that may participate in the pathophysiology of progressive renal disease by concomitantly affecting the hemodynamics of the glomerular microcirculation as well as growth related responses of MC to injury.
血管紧张素II(Ang II)在肾脏疾病进展的发病机制中所公认的作用不能仅仅归因于其血流动力学效应。实际上,由Ang II驱动的生长刺激信号促进系膜细胞(MC)肥大和细胞外基质产生,这是进行性肾小球损伤的显著特征。超氧阴离子(O2-)与一氧化氮(一种内源性血管舒张剂,可抑制生长因子刺激的MC生长和基质产生)强烈相互作用。此外,作为细胞内信号的O2-与生长相关反应(如丝裂原活化蛋白(MAP)激酶的激活)有关。本文报道的研究旨在调查:(a)Ang II是否诱导MC产生O2-,以及(b)O2-产生增加是否引发MC的生长反应。
将MC暴露于Ang II 24或48小时。在一些实验中,除了Ang II外,还将MC暴露于:二苯基碘鎓(DPI),一种含黄素的NADH/NADPH氧化酶抑制剂;氯沙坦(LOS),一种Ang II 1型(AT1)受体阻滞剂;PD 98059,一种MAP激酶抑制剂;蛋白激酶C抑制剂Calphostin C或H-7;以及酪氨酸激酶抑制剂赫伯霉素A或染料木黄酮。
Ang II(10^-5 M至10^-8 M)剂量依赖性地使MC的O2-产生增加,比对照高出125%(半数有效剂量5×10^-7 M)。LOS以及DPI和PKC抑制剂可阻断Ang II刺激的MC O2-产生。Ang II剂量依赖性地增加MC的3H-亮氨酸掺入、MC蛋白含量(MC肥大的两个标志物)以及作为MC增生标志物的3H-胸腺嘧啶核苷掺入。MAP激酶的特异性抑制剂PD98059可预防Ang II诱导的MC肥大。此外,LOS、DPI和PKC抑制剂各自独立抑制MC的3H-亮氨酸掺入,从而证实了Ang II诱导的O2-在驱动MC肥大方面的特异性。
当前研究表明Ang II与MC O2-产生之间存在一种先前未被认识的联系,这可能通过同时影响肾小球微循环的血流动力学以及MC对损伤的生长相关反应而参与进行性肾脏疾病的病理生理学过程。